


CERTIFICATE OF ELECTRONIC TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
August 16, 2011 Date	 Steven L. Highlander

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Malte PETERS *et al.*

Serial No.: 10/589,450

Filed: August 11, 2006

For: ANTI-EPCAMIMMUNOGLOBULINS

Group Art Unit: 1641

Examiner: Bradley Duffy

Atty. Dkt. No.: MCMT.P0006US

Confirmation No.: 5684

**DECLARATION OF SABINE KAUBITZSCH UNDER 37 C.F.R. §1.132**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

I, Dr. Sabine Kaubitzsch, do declare that:

1. I am a citizen of Germany residing at Marschall 20a, 83607 Holzkirchen, Germany. I currently hold the position of Medical Director, Clinical Development Department, at Micromet AG, Munich, Germany. In this position, I am responsible for multicenter clinical studies of MT201, also known as adecatumumab, which is a fully human recombinant IgG1 antibody that specifically binds to the epithelial cell adhesion molecule (EpCAM), and which is the subject matter of the above-identified patent application. A copy of my *curriculum vitae* is attached herewith.

2. In particular, I am responsible for an open-label, multicenter Phase 1b dose-escalation study to investigate the safety and tolerability of a combination regimen of adecatumumab and docetaxel in patients with EpCAM-positive relapsed or primary refractory advanced stage breast cancer.